AU708061B2 - OMP26 antigen from haemophilus influenzae - Google Patents

OMP26 antigen from haemophilus influenzae Download PDF

Info

Publication number
AU708061B2
AU708061B2 AU62363/96A AU6236396A AU708061B2 AU 708061 B2 AU708061 B2 AU 708061B2 AU 62363/96 A AU62363/96 A AU 62363/96A AU 6236396 A AU6236396 A AU 6236396A AU 708061 B2 AU708061 B2 AU 708061B2
Authority
AU
Australia
Prior art keywords
protein
omp26
influenzae
vaccine formulation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62363/96A
Other languages
English (en)
Other versions
AU6236396A (en
Inventor
Allan Cripps
Jennelle Kyd
Christopher John Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CORTECS INTERNATIONAL Ltd
Original Assignee
CORTECS INTERNATIONAL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CORTECS INTERNATIONAL Ltd filed Critical CORTECS INTERNATIONAL Ltd
Publication of AU6236396A publication Critical patent/AU6236396A/en
Application granted granted Critical
Publication of AU708061B2 publication Critical patent/AU708061B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
AU62363/96A 1995-06-27 1996-06-27 OMP26 antigen from haemophilus influenzae Ceased AU708061B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513074.6A GB9513074D0 (en) 1995-06-27 1995-06-27 Novel anigen
GB9513074 1995-06-27
PCT/GB1996/001549 WO1997001638A1 (en) 1995-06-27 1996-06-27 Omp26 antigen from haemophilus influenzae

Publications (2)

Publication Number Publication Date
AU6236396A AU6236396A (en) 1997-01-30
AU708061B2 true AU708061B2 (en) 1999-07-29

Family

ID=10776746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62363/96A Ceased AU708061B2 (en) 1995-06-27 1996-06-27 OMP26 antigen from haemophilus influenzae

Country Status (18)

Country Link
US (4) US6245338B1 (enExample)
EP (1) EP0835313B1 (enExample)
JP (2) JPH11510373A (enExample)
KR (1) KR19990028423A (enExample)
CN (1) CN1144875C (enExample)
AT (1) ATE317013T1 (enExample)
AU (1) AU708061B2 (enExample)
CA (1) CA2225405A1 (enExample)
DE (1) DE69635783T2 (enExample)
ES (1) ES2259443T3 (enExample)
GB (1) GB9513074D0 (enExample)
MX (1) MX9710412A (enExample)
NO (1) NO976119L (enExample)
NZ (1) NZ311120A (enExample)
RU (1) RU2221045C2 (enExample)
TW (1) TW457247B (enExample)
WO (1) WO1997001638A1 (enExample)
ZA (1) ZA965482B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
GB9904183D0 (en) * 1999-02-24 1999-04-14 Smithkline Beecham Biolog Novel compounds
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU2002211999A1 (en) * 2000-10-02 2002-04-15 Id Biomedical Corporation Haemophilus influenzae antigens and corresponding DNA fragments
RU2185191C1 (ru) * 2001-02-01 2002-07-20 Ростовский научно-исследовательский институт микробиологии и паразитологии Способ получения антигенного препарата haemophilus influenzae типа b (hib)
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
BRPI0609460A2 (pt) * 2005-03-30 2010-04-13 Novartis Vaccines & Diagnostics Inc haemophilus influenzae tipo b
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
KR100743604B1 (ko) * 2005-12-05 2007-07-27 볼보 컨스트럭션 이키프먼트 홀딩 스웨덴 에이비 차량용 머플러 구조
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
NO346497B1 (no) 2006-01-17 2022-09-05 Arne Forsgren Overflateeksponert haemophilus influenzae protein (protein E, pE)
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2717909B1 (en) 2011-06-04 2017-12-06 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
RU2727476C2 (ru) * 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
CN104370997B (zh) * 2014-09-24 2018-07-31 陈辉 去除生物制品中细菌内毒素的试剂盒、方法及其生物制品的制备方法
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462210B1 (en) * 1989-03-09 1994-09-07 Praxis Biologics, Inc. Vaccines for nontypable haemophilus influenzae
GB8924473D0 (en) * 1989-10-31 1989-12-20 Connaught Lab Outer membrane protein p1 and peptides of haemophilus influenzae b
GB9224584D0 (en) * 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAN. J. MICROBIOL. 29(1983) 280-7 *
INFECT. & IMMUN. 62(12)(1994), 5652-8 *

Also Published As

Publication number Publication date
US6284477B1 (en) 2001-09-04
ZA965482B (en) 1997-12-29
WO1997001638A1 (en) 1997-01-16
DE69635783D1 (de) 2006-04-13
JPH11510373A (ja) 1999-09-14
US6254875B1 (en) 2001-07-03
JP2009034107A (ja) 2009-02-19
CN1144875C (zh) 2004-04-07
DE69635783T2 (de) 2006-11-02
CA2225405A1 (en) 1997-01-16
CN1189186A (zh) 1998-07-29
US6313281B1 (en) 2001-11-06
US6245338B1 (en) 2001-06-12
MX9710412A (es) 1998-07-31
NZ311120A (en) 1999-10-28
NO976119D0 (no) 1997-12-29
EP0835313A1 (en) 1998-04-15
EP0835313B1 (en) 2006-02-01
GB9513074D0 (en) 1995-08-30
KR19990028423A (ko) 1999-04-15
AU6236396A (en) 1997-01-30
NO976119L (no) 1998-02-26
ES2259443T3 (es) 2006-10-01
ATE317013T1 (de) 2006-02-15
RU2221045C2 (ru) 2004-01-10
TW457247B (en) 2001-10-01

Similar Documents

Publication Publication Date Title
AU708061B2 (en) OMP26 antigen from haemophilus influenzae
JP5566684B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
EP0717106B1 (en) Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
CA2040544C (en) Actinobacillus pleuropneumoniae subunit vaccine
CA2098448A1 (en) Dna fragments which encode the transferrin receptor subunits of neisseria meningitidis
Denich et al. Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing
US20090246228A1 (en) Moraxella catarrhalis Proteins
JP2009029825A (ja) 抗原
JP2777894B2 (ja) コレラワクチン
Lai et al. Protection of mice against experimental murine mycoplasmosis by a Mycoplasma pulmonis immunogen in lysogenized Escherichia coli
JP3693900B2 (ja) １ａ５ｂ構造を有する蛋白質の製造法
WO1994006911A2 (en) Mycoplasma pulmonis antigens and methods and compositions for use in cloning and vaccination
MXPA00011069A (en) Moraxella catarrhalis proteins